7811 Montrose Rd Suite 310
Potomac, MD 20854

Eskata®

Why Eskata?

Until now there have been no FDA-approved topical treatments for raised SKs.

Raised seborrheic keratoses (SKs) are known to appear in highly visible locations

Common treatment modalities:


Many patients are willing to self-pay for SK treatment

*Survey not limited to patients with raised SKs.


The Eskata Difference

FDA-Approved Formulation

  • ESKATA contains 40% pharmaceutical grade H2O2 (hydrogen peroxide) that meets FDA guidelines and is FDA-approved for the treatment of raised seborrheic keratoses
  • The active pharmaceutical ingredient is housed in a proprietary solution that increases spreadability while maintaining stability(4)
  • This unique combination was evaluated in pivotal trials that included over 900 subjects*

Novel Application

  • Doe-foot applicator
  • Applicator tip design allows optimal spreadability over targeted lesions
  • Flame-sealed crushable ampule provides shelf stability for 2 years at room temperature

References

  1. Data on file. Aclaris Therapeutics, Inc. 2017.
  2. Jackson JM, Alexis A, Berman B, Berson DS, Taylor S, Weiss JS. Current Understanding of Seborrheic Keratosis: Prevalence, Etiology, Clinical Presentation, Diagnosis, and Management. J Drugs Dermatol. 2015;14(10):1119-1125.
  3. Hafner C, Vogt T. Seborrheic keratosis. J Dtsch Dermatol Ges. 2008;6(8):664-667.
  4. ESKATA Full Prescribing Information. Aclaris Therapeutics, Inc. 2017.

Schedule Consultation